C
Charles Koller
Researcher at University of Texas MD Anderson Cancer Center
Publications - 192
Citations - 15588
Charles Koller is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Leukemia & Fludarabine. The author has an hindex of 59, co-authored 192 publications receiving 15226 citations. Previous affiliations of Charles Koller include National Institutes of Health & University of Southern California.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating,Susan O'Brien,Maher Albitar,Susan Lerner,William Plunkett,Francis J. Giles,Michael Andreeff,Jorge E. Cortes,Stefan Faderl,Deborah A. Thomas,Charles Koller,William G. Wierda,Michelle A. Detry,Alice Lynn,Hagop M. Kantarjian +14 more
TL;DR: FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
Journal ArticleDOI
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Alvaro Aguayo,Hagop M. Kantarjian,Taghi Manshouri,Cristi Gidel,Elihu H. Estey,Deborah A. Thomas,Charles Koller,Zeev Estrov,Susan O'Brien,Michael J. Keating,Emil J. Freireich,Maher Albitar +11 more
TL;DR: The data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in theLeukemogenic process.
Journal ArticleDOI
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
Hagop M. Kantarjian,Deborah A. Thomas,Susan O'Brien,Jorge E. Cortes,Francis J. Giles,Sima Jeha,Carlos E. Bueso-Ramos,Sherry Pierce,Jianqin Shan,Charles Koller,Miloslav Beran,Michael J. Keating,Emil J. Freireich +12 more
TL;DR: The current analysis updated the long‐term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD) program, with a median follow‐up time of 63 months.
Journal ArticleDOI
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William G. Wierda,Susan O'Brien,Sijin Wen,Stefan Faderl,Guillermo Garcia-Manero,Deborah A. Thomas,Kim Anh Do,Jorge E. Cortes,Charles Koller,Miloslav Beran,Alessandra Ferrajoli,Francis J. Giles,Susan Lerner,Maher Albitar,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL, and molecular remissions were achieved in a third of patients achieving CR.